|
See related Revlimid cap information |
|
|
|
Manufacturer |
Celgene |
|
Distributor |
Zuellig |
|
Contents |
Lenalidomide |
|
Indications |
In combination w/ dexamethasone for the treatment of relapse or refractory multiple myeloma patients who have received at least 1 prior therapy.
Click to view Revlimid detailed prescribing infomation |
|
Dosage |
Starting dose: 25 mg once daily on days 1-21 of repeated 28-day cycle w/ dexamethasone 40 mg once daily on days 1-4, 9-12 & 17-20 of each 28-day cycle for the 1st 4 cycles of therapy, thereafter dexamethasone 40 mg once daily on days 1-4 every 28 days.
Click to view Revlimid detailed prescribing infomation |
|
Overdosage |
View Revlimid overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food (Swallow whole, do not break/chew/open.). |
|
Contraindications |
Pregnancy, women of childbearing potential.
Click to view Revlimid detailed prescribing infomation |
|
Warnings |
For additional cautionary notes to warn of the potential risk of using the medicine... click to view Revlimid detailed prescribing infomation |
|
Special Precautions |
Patients taking OC prior to therapy (increased risk of venous thromboembolism). Do not donate blood or semen during therapy or for 4 wk after cessation of treatment. Perform complete blood cell count including WBC w/ differential count, platelet count, Hb & haematorcrit at baseline, wkly for the 1st 8 wk & mthly thereafter. Concomitant myelosuppressive agents. Renal impairment. Monitor for thromboembolism, signs of bleeding (including petechiae & epistaxes), thyroid function, risk of tumour lysis syndrome. Lactose intolerance. May impair ability to drive or operate machinery. Childn & elderly. Lactation.
Click to view Revlimid detailed prescribing infomation |
|
Adverse Drug Reactions |
Venous thromboembolism, neutropenia, fatigue, asthenia, constipation, muscle cramp & weakness, thrombocytopenia, anaemia, diarrhoea, rash, nausea, increased & decreased wt, peripheral oedema, insomnia.
View ADR Monitoring Form |
|
Drug Interactions |
Erythropoietic agents, other agents associated w/ increased risk of thrombosis (eg hormone replacement therapy), OC, warfarin, digoxin.
View more drug interactions with Revlimid |
|
Pregnancy Category (US FDA) |
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there is evidence of foetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant. |
|
Storage |
View Revlimid storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Revlimid description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Revlimid mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Revlimid capsule |
|
Revlimid 5 mg x 21's |
|
Revlimid 10 mg x 21's |
|
Revlimid 15 mg x 21's |
|
Revlimid 25 mg x 21's |
|
|
|
Manufacturer: |
Celgene |
|
Distributor: |
Zuellig |
|
Marketer: |
Invida |
|
 |
|
|
|
